Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rhinaction is a natural nasal decongestant spray classified as a Class IIa Medical Device in Europe. Developed by Laboratoire de la Mer, it is indicated for the relief of symptoms associated with acute rhinitis (common cold), colds, and rhinopharyngitis in adults and children over 3 years of age. The formulation consists of hypertonic seawater (2.2% total salts) combined with a complex of three essential oils: Ravintsara, Thyme Linalool, and Field Mint. It works through an osmotic mechanism, drawing fluid from swollen nasal tissues to reduce congestion, while also fluidifying excess mucus and purifying the nasal cavities. Unlike conventional pharmacological decongestants, Rhinaction is free of vasoconstrictors (such as xylometazoline) and corticosteroids, and it does not cause rebound effects or habituation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Rhinaction.